Paresis Following Type A Botulinum Toxin (Dysport) Injection: A Case Report
Journal of Cellular & Molecular Anesthesia · 2024
DOI: 10.5812/jcma-146536 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cellular & Molecular Anesthesia, 2024. Verfasst von Sara Salarian und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
: Primary hyperhidrosis (PH) is a condition characterized by excessive sweating. Primary treatment options include antiperspirants or anticholinergics for symptomatic relief, while axillary and palmar hyperhidrosis can be addressed with surgery. Botulinum toxin type A (BTX-A) is a significant treatment option for these patients. This toxin inhibits the release of acetylcholine, preventing overactive eccrine sweat glands from causing excessive sweating. Despite its effectiveness in treating various neurological and cosmetic conditions, Botox may pose the risk of severe side effects resulting from local or systemic drug release. We report the case of a 21-year-old woman who developed weakness in all four limbs, dyspnea, dysphagia, and blurred vision two weeks after botulinum toxin injection for hyperhidrosis treatment.
Zitieren
APA
Salarian, S., Raoufi, M., Asgari, S., Behnaz, F., & Lima, B. S. (2024). Paresis Following Type A Botulinum Toxin (Dysport) Injection: A Case Report. Journal of Cellular & Molecular Anesthesia. https://doi.org/10.5812/jcma-146536
Vancouver
Salarian S, Raoufi M, Asgari S, Behnaz F, Lima BS. Paresis Following Type A Botulinum Toxin (Dysport) Injection: A Case Report. Journal of Cellular & Molecular Anesthesia. 2024. doi:10.5812/jcma-146536
BibTeX
@article{Salarian2024,
author = {Salarian, Sara and Raoufi, Masoomeh and Asgari, Sogol and Behnaz, Faranak and Lima, Behnam Safarpour},
title = {Paresis Following Type A Botulinum Toxin (Dysport) Injection: A Case Report},
journal = {Journal of Cellular & Molecular Anesthesia},
year = {2024},
doi = {10.5812/jcma-146536}
}
EUVIMED